Verwandte Artikel zu Rift-lines within european regulatory framework for...

Rift-lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and ... FRAMEWORK FOR BIOSIMILARS WHEN TAKING - Softcover

 
9783954891870: Rift-lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and ... FRAMEWORK FOR BIOSIMILARS WHEN TAKING
Alle Exemplare der Ausgabe mit dieser ISBN anzeigen:
 
 
Reseña del editor:
Biopharmaceutical medicinal products (biologics) represent a huge financial market. Thus upon patent protection expiry of the innovator (reference) biologic there is interest from industry to gain a portion of this market by launching a 'similar' biologic at a reduced development cost, thus boosting potential gains. The EMA responded to this desire and lead the guidance process with industry on the topic of biosimilars. Based on the experience gained with biosimilars in the past, the EMA started to introduce a second generation series of guidance documents, which take into account the past, current and possibly future challenges of biosimilars. Those proposals were evaluated by EMA and partially incorporated into new guidance documents. This work highlights the challenges and risks associated with biosimilar submissions for large and complex bio-molecules such antibodies. Results: There are unaddressed questions for the regulator with regard to the unsolved dynamic of heterogeneity and variations of the quality profile, which have potential implications on safety and efficacy. This is neglected and not taken into account seriously enough by the stakeholders. Solution: Further, the only (in my view) progressive way to deal with such foreseeable situations from the biosimilar developer's point of view is to incorporate a design space.
Biografía del autor:
The author works in the life-science industry for over 7 years now. His educational and scientific background is in immunology, as he graduated at the Max Planck Institute for Immunology in Freiburg. Further he completed a MSc. in pharmaceutical quality assurance and regulatory affairs at the Dublin Institute of Technology.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

  • VerlagAnchor Academic Publishing
  • Erscheinungsdatum2013
  • ISBN 10 3954891875
  • ISBN 13 9783954891870
  • EinbandTapa blanda
  • Anzahl der Seiten284

Versand: EUR 23,00
Von Deutschland nach USA

Versandziele, Kosten & Dauer

In den Warenkorb

Weitere beliebte Ausgaben desselben Titels

9783656517399: Rift-lines within European regulatory framework for Biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account

Vorgestellte Ausgabe

ISBN 10:  3656517398 ISBN 13:  9783656517399
Verlag: GRIN Verlag, 2013
Softcover

Beste Suchergebnisse bei AbeBooks

Foto des Verkäufers

Malik Osmane
ISBN 10: 3954891875 ISBN 13: 9783954891870
Neu Taschenbuch Anzahl: 2
Print-on-Demand
Anbieter:
BuchWeltWeit Ludwig Meier e.K.
(Bergisch Gladbach, Deutschland)
Bewertung

Buchbeschreibung Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Biopharmaceutical medicinal products (biologics) represent a huge financial market. Thus upon patent protection expiry of the innovator (reference) biologic there is interest from industry to gain a portion of this market by launching a 'similar' biologic at a reduced development cost, thus boosting potential gains. The EMA responded to this desire and lead the guidance process with industry on the topic of biosimilars. Based on the experience gained with biosimilars in the past, the EMA started to introduce a second generation series of guidance documents, which take into account the past, current and possibly future challenges of biosimilars. Those proposals were evaluated by EMA and partially incorporated into new guidance documents. This work highlights the challenges and risks associated with biosimilar submissions for large and complex bio-molecules such antibodies. Results: There are unaddressed questions for the regulator with regard to the unsolved dynamic of heterogeneity and variations of the quality profile, which have potential implications on safety and efficacy. This is neglected and not taken into account seriously enough by the stakeholders. Solution: Further, the only (in my view) progressive way to deal with such foreseeable situations from the biosimilar developer's point of view is to incorporate a design space. 284 pp. Englisch. Bestandsnummer des Verkäufers 9783954891870

Weitere Informationen zu diesem Verkäufer | Verkäufer kontaktieren

Neu kaufen
EUR 54,99
Währung umrechnen

In den Warenkorb

Versand: EUR 23,00
Von Deutschland nach USA
Versandziele, Kosten & Dauer
Foto des Verkäufers

Malik Osmane
ISBN 10: 3954891875 ISBN 13: 9783954891870
Neu Taschenbuch Anzahl: 1
Print-on-Demand
Anbieter:
AHA-BUCH GmbH
(Einbeck, Deutschland)
Bewertung

Buchbeschreibung Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Biopharmaceutical medicinal products (biologics) represent a huge financial market. Thus upon patent protection expiry of the innovator (reference) biologic there is interest from industry to gain a portion of this market by launching a 'similar' biologic at a reduced development cost, thus boosting potential gains. The EMA responded to this desire and lead the guidance process with industry on the topic of biosimilars. Based on the experience gained with biosimilars in the past, the EMA started to introduce a second generation series of guidance documents, which take into account the past, current and possibly future challenges of biosimilars. Those proposals were evaluated by EMA and partially incorporated into new guidance documents. This work highlights the challenges and risks associated with biosimilar submissions for large and complex bio-molecules such antibodies. Results: There are unaddressed questions for the regulator with regard to the unsolved dynamic of heterogeneity and variations of the quality profile, which have potential implications on safety and efficacy. This is neglected and not taken into account seriously enough by the stakeholders. Solution: Further, the only (in my view) progressive way to deal with such foreseeable situations from the biosimilar developer's point of view is to incorporate a design space. Bestandsnummer des Verkäufers 9783954891870

Weitere Informationen zu diesem Verkäufer | Verkäufer kontaktieren

Neu kaufen
EUR 54,99
Währung umrechnen

In den Warenkorb

Versand: EUR 32,99
Von Deutschland nach USA
Versandziele, Kosten & Dauer
Foto des Verkäufers

Osmane, Malik
ISBN 10: 3954891875 ISBN 13: 9783954891870
Neu Softcover Anzahl: > 20
Print-on-Demand
Anbieter:
moluna
(Greven, Deutschland)
Bewertung

Buchbeschreibung Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Biopharmaceutical medicinal products (biologics) represent a huge financial market. Thus upon patent protection expiry of the innovator (reference) biologic there is interest from industry to gain a portion of this market by launching a similar biologic a. Bestandsnummer des Verkäufers 5727179

Weitere Informationen zu diesem Verkäufer | Verkäufer kontaktieren

Neu kaufen
EUR 54,99
Währung umrechnen

In den Warenkorb

Versand: EUR 48,99
Von Deutschland nach USA
Versandziele, Kosten & Dauer
Beispielbild für diese ISBN

Osmane, Malik
ISBN 10: 3954891875 ISBN 13: 9783954891870
Neu PAP Anzahl: > 20
Print-on-Demand
Anbieter:
PBShop.store US
(Wood Dale, IL, USA)
Bewertung

Buchbeschreibung PAP. Zustand: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Bestandsnummer des Verkäufers L0-9783954891870

Weitere Informationen zu diesem Verkäufer | Verkäufer kontaktieren

Neu kaufen
EUR 170,29
Währung umrechnen

In den Warenkorb

Versand: Gratis
Innerhalb der USA
Versandziele, Kosten & Dauer
Beispielbild für diese ISBN

Malik Osmane
ISBN 10: 3954891875 ISBN 13: 9783954891870
Neu Paperback Anzahl: 10
Anbieter:
Chiron Media
(Wallingford, Vereinigtes Königreich)
Bewertung

Buchbeschreibung Paperback. Zustand: New. Bestandsnummer des Verkäufers 6666-IUK-9783954891870

Weitere Informationen zu diesem Verkäufer | Verkäufer kontaktieren

Neu kaufen
EUR 152,97
Währung umrechnen

In den Warenkorb

Versand: EUR 17,50
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer
Beispielbild für diese ISBN

Osmane, Malik
ISBN 10: 3954891875 ISBN 13: 9783954891870
Neu Softcover Anzahl: > 20
Anbieter:
Lucky's Textbooks
(Dallas, TX, USA)
Bewertung

Buchbeschreibung Zustand: New. Bestandsnummer des Verkäufers ABLIING23Apr0316110173640

Weitere Informationen zu diesem Verkäufer | Verkäufer kontaktieren

Neu kaufen
EUR 169,19
Währung umrechnen

In den Warenkorb

Versand: EUR 3,74
Innerhalb der USA
Versandziele, Kosten & Dauer
Beispielbild für diese ISBN

Osmane, Malik
ISBN 10: 3954891875 ISBN 13: 9783954891870
Neu PAP Anzahl: > 20
Print-on-Demand
Anbieter:
PBShop.store UK
(Fairford, GLOS, Vereinigtes Königreich)
Bewertung

Buchbeschreibung PAP. Zustand: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Bestandsnummer des Verkäufers L0-9783954891870

Weitere Informationen zu diesem Verkäufer | Verkäufer kontaktieren

Neu kaufen
EUR 161,96
Währung umrechnen

In den Warenkorb

Versand: EUR 29,18
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer